sodium 2-(2-tritylaminothiazol-4-yl)-(Z)-2-(tritylhydroxyimino)acetate

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: sodium 2-(2-tritylaminothiazol-4-yl)-(Z)-2-(tritylhydroxyimino)acetate
• 英文别名: (Z)-(2-tritylamino-thiazol-4yl)-2-trityloxyimino-acetic acid sodium salt；sodium (Z)-2-(2-tritylaminothiazol-4-yl)-2-trityloxyiminoacetate；Sodium 2-(2-triphenylmethylaminothiazol-4-yl)2-Z-triphenylmethoxyiminoacetate；sodium;(2Z)-2-[2-(tritylamino)-1,3-thiazol-4-yl]-2-trityloxyiminoacetate
• 化学式: C₄₃H₃₂N₃O₃S*Na
• 分子量: 693.801
• InChiKey: XDHGLJUEWDPPEV-IDVGRLRUSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  5.01
• 重原子数：
  51
• 可旋转键数：
  12
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  115
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  sodium 2-(2-tritylaminothiazol-4-yl)-(Z)-2-(tritylhydroxyimino)acetate 在 甲酸 、 苯甲醚 、 N,N-二甲基苯胺 、 三氟乙酸 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 反应 4.5h， 生成 头孢地尼
  参考文献：
  名称：

  An alternative procedure for preparation of cefdinir

  摘要：

  Cefdinir, a broad spectrum third-generation cephalosporin for oral administration, was prepared by the following synthetic pathway: synthesis of diphenylmethyl 7beta-amino-3-vinyl-3-cephem-4-carboxylate hydrochloride from 7-aminocephalosporanic acid (7-ACA), preparation of sodium 2-(2-tritylaminothiazol-4-yl)-(Z)-2-(tritylhydroxyimino) acetate from ethyl acetoacetate, coupling of both intermediaries to obtain diphenylmethyl 7beta-[2-(2-tritylaminothiazol-4-yl)-(Z)-2-tritylhydroxyimino-3-vinyl-3-cephem-4-carboxylate and final cleavage of trityl and diphenylmethyl protective groups. This procedure allows to obtain better yields of cefdinir and to avoid the use of diketene during the synthesis of this antibiotic by the previously reported method.

  DOI：

  10.1016/s0014-827x(03)00063-6
• 作为产物：
  描述：

  (Z)-2-[2-(三苯甲基氨基)噻唑-4-基]-2-(三苯甲基氧基亚氨基)乙酸乙酯 在 sodium hydroxide 作用下， 以 水 、 丁酮 为溶剂， 反应 2.25h， 以90.82%的产率得到sodium 2-(2-tritylaminothiazol-4-yl)-(Z)-2-(tritylhydroxyimino)acetate
  参考文献：
  名称：

  Stable bioavailable crystalline form or cefdinir and a process for the preparation thereof

  摘要：

  本发明涉及第三代头孢菌素抗生素头孢噻肟的稳定且生物利用度高的结晶形式，以及其制备方法。本发明还涉及一种含有新型结晶头孢噻肟的药物组合物，可用于治疗细菌感染等疾病。

  公开号：

  US20050245738A1

文献信息

• Cephalosporin derivatives
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：US05332731A1

  公开（公告）日：1994-07-26

  A new class of cephalosporin derivatives is provided, which is useful as antibacterial agent to be particularly suitable for oral administrations in mammals including man, and which is represented by general formula (I) ##STR1## wherein R.sup.1 is a hydrogen atom or a lower alkyl group; R.sup.2 is a hydrogen atom or an ester-forming group capable of being cleaved easily with an esterase existing in the digestive tracts; n is an integer of zero or 1; Z is a saturated heterocyclic group containing one or two oxygen atoms as the hetero-atoms with or without one or more lower alkyl substituents, or a pharmaceutically acceptable salt thereof.

  提供了一类新的头孢菌素衍生物，其作为抗菌剂特别适用于包括人类在内的哺乳动物的口服给药，其由通式（I）表示：##STR1##其中R1是一个氢原子或低级烷基组；R2是一个氢原子或能够被消化道中存在的酯酶轻易裂解的酯形成组；n是零或1的整数；Z是一个含有作为杂原子的一个或两个氧原子的饱和杂环组，带有或不带有一个或多个低级烷基取代基，或其药学上可接受的盐。
• Novel amino chlorothiazole compounds
  申请人：Microcide Pharmaceuticals, Inc.

  公开号：EP1059293A1

  公开（公告）日：2000-12-13

  The invention relates to novel amino chlorothiazole compounds and to novel methods for producing the novel compounds. The compounds are useful in the production of cephalosporin antiobiotics.

  该发明涉及新型氨基氯噻唑化合物以及生产这些新化合物的新方法。这些化合物在头孢菌素类抗生素的生产中很有用。
• Cephalosporin derivatives and pharmaceutical compositions
  申请人：Beecham Group p.l.c.

  公开号：US05158946A1

  公开（公告）日：1992-10-27

  .beta.-Lactam compounds of the formula (I) including pharmaceutically acceptable salts and in vivo hydrolysable esters, processes for their preparation and their use as antibiotics: ##STR1## wherein R.sup.1 is hydrogen, methoxy or formamido; R.sup.2 is an acyl group, in particular that of an antibacterially active cephalosporin; R.sup.3 is hydrogen or a readily removable carboxy protecting group (such as a pharmaceutically acceptable in-vivo hydrolysable ester group); R.sup.4 is a .gamma.- or .delta.-lactone ring optionally containing one or (where applicable) two endocyclic double bonds, which ring is optionally substituted at any carbon atom by alkyl, dialkylamino, alkoxy, hydroxy, halogen or aryl, which in the case of more than one substituent may be the same or different, or is optionally di-substituted at two adjacent carbon atoms, which are available for substitution, to form an aromatic fused bicyclic system; x and y are independently 0 or 1; X is S, SO, SO.sub.2, O or CH.sub.2 ; and Y is O or S.

  .beta.-内酰胺化合物的化学式（I），包括药学上可接受的盐和体内水解酯，其制备过程和用作抗生素的方法：##STR1## 其中R.sup.1是氢，甲氧基或甲酰胺基; R.sup.2是酰基，特别是抗菌活性头孢菌素的酰基; R.sup.3是氢或易于去除的羧基保护基（例如药学上可接受的体内水解酯基）; R.sup.4是含有一个或（适用时）两个内环双键的γ-或δ-内酯环，该环在任何碳原子上均可选择性地取代为烷基，双烷基氨基，烷氧基，羟基，卤素或芳基，在存在多个取代基的情况下，可能相同或不同，或者在两个相邻的可取代碳原子处选择性地双取代，以形成芳香融合的双环系统; x和y独立地为0或1; X为S，SO，SO.sub.2，O或CH.sub.2; Y为O或S。
• Cephaloporins and homologues, preparations and pharmaceutical
  申请人：Pzifer Inc.

  公开号：US06020329A1

  公开（公告）日：2000-02-01

  .beta.-Lactam antibiotics of formula (I) or a salt thereof, wherein R.sup.1 is hydrogen, methoxy or formamido; R.sup.2 is an acy group; CO.sub.2 R.sup.3 is a carboxy group or a carboxylate anion, or R.sup.3 is a readily removable carboxy protecting group; R.sup.4 represents up to four substituents; X is S, SO, SO.sub.2, O or CH.sub.2 ; m is 1 or 2; and n is 0, useful in the treatment of bacterial infec ##STR1##

  式(I)的.beta.-内酰胺抗生素或其盐，其中R.sup.1为氢、甲氧基或甲酰胺基；R.sup.2为酰基；CO.sub.2R.sup.3为羧基或羧酸盐，或R.sup.3为易于去除的羧保护基；R.sup.4代表多达四个取代基；X为S、SO、SO.sub.2、O或CH.sub.2；m为1或2；n为0，有用于治疗细菌感染的作用。
• Cephaloporins and homologues
  申请人：Pfizer Inc.

  公开号：US06077952A1

  公开（公告）日：2000-06-20

  A compound of formula (II) or a salt: ##STR1##

  化合物公式（II）或其盐：##STR1##